Trial Profile
Prospective Observational Study for Lesion of Neoatherosclerosis: The Efficacy of Alirocumab for the Neoatherosclerosis Reaction Investigated by Serial Optical Coherence Tomography
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Rosuvastatin
- Indications Coronary artery disease; Stent thrombosis
- Focus Therapeutic Use
- Acronyms POLARIS
- 22 Sep 2017 New trial record